The Role of Heparin in COVID-19: An Update after Two Years of Pandemics
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/11/3099 |
| _version_ | 1797492902555811840 |
|---|---|
| author | Marco Mangiafico Andrea Caff Luca Costanzo |
| author_facet | Marco Mangiafico Andrea Caff Luca Costanzo |
| author_sort | Marco Mangiafico |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism for the development of complications in an acute phase of the illness and for several postdischarge sequalae. Heparin has been shown to have a positive impact on COVID-19 due to its anticoagulant function. Moreover, several other biological actions of heparin were postulated: a potential anti-inflammatory and antiviral effect through the main protease (M<sup>pro</sup>) and heparansulfate (HS) binding and a protection from the damage of vascular endothelial cells. In this paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage. |
| first_indexed | 2024-03-10T01:11:22Z |
| format | Article |
| id | doaj.art-798015daa1a74b13ba3b6cb0c6716ee2 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:11:22Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-798015daa1a74b13ba3b6cb0c6716ee22023-11-23T14:16:47ZengMDPI AGJournal of Clinical Medicine2077-03832022-05-011111309910.3390/jcm11113099The Role of Heparin in COVID-19: An Update after Two Years of PandemicsMarco Mangiafico0Andrea Caff1Luca Costanzo2Unit of Internal Medicine, Policlinico “G. Rodolico—San Marco”, 95100 Catania, ItalyUnit of Internal Medicine, Policlinico “G. Rodolico—San Marco”, 95100 Catania, ItalyUnit of Angiology, Department of Cardio-Thoraco-Vascular, Policlinico “G. Rodolico—San Marco” University Hospital, University of Catania, 95100 Catania, ItalyCoronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism for the development of complications in an acute phase of the illness and for several postdischarge sequalae. Heparin has been shown to have a positive impact on COVID-19 due to its anticoagulant function. Moreover, several other biological actions of heparin were postulated: a potential anti-inflammatory and antiviral effect through the main protease (M<sup>pro</sup>) and heparansulfate (HS) binding and a protection from the damage of vascular endothelial cells. In this paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage.https://www.mdpi.com/2077-0383/11/11/3099COVID-19heparinlow molecular weight heparincoagulopathythromboprophylaxis |
| spellingShingle | Marco Mangiafico Andrea Caff Luca Costanzo The Role of Heparin in COVID-19: An Update after Two Years of Pandemics Journal of Clinical Medicine COVID-19 heparin low molecular weight heparin coagulopathy thromboprophylaxis |
| title | The Role of Heparin in COVID-19: An Update after Two Years of Pandemics |
| title_full | The Role of Heparin in COVID-19: An Update after Two Years of Pandemics |
| title_fullStr | The Role of Heparin in COVID-19: An Update after Two Years of Pandemics |
| title_full_unstemmed | The Role of Heparin in COVID-19: An Update after Two Years of Pandemics |
| title_short | The Role of Heparin in COVID-19: An Update after Two Years of Pandemics |
| title_sort | role of heparin in covid 19 an update after two years of pandemics |
| topic | COVID-19 heparin low molecular weight heparin coagulopathy thromboprophylaxis |
| url | https://www.mdpi.com/2077-0383/11/11/3099 |
| work_keys_str_mv | AT marcomangiafico theroleofheparinincovid19anupdateaftertwoyearsofpandemics AT andreacaff theroleofheparinincovid19anupdateaftertwoyearsofpandemics AT lucacostanzo theroleofheparinincovid19anupdateaftertwoyearsofpandemics AT marcomangiafico roleofheparinincovid19anupdateaftertwoyearsofpandemics AT andreacaff roleofheparinincovid19anupdateaftertwoyearsofpandemics AT lucacostanzo roleofheparinincovid19anupdateaftertwoyearsofpandemics |